Skip to main content

Table 1 Main sociodemographic characteristics at inclusion and clinical profile of COPD patients prescribed with FSC

From: Real-life use of fluticasone propionate/salmeterol in patients with chronic obstructive pulmonary disease: a French observational study

  GPs N patients (n = 352) Pulmonologists N patients (n = 358)
Age in years, mean (SD) 61.6 (11.4) 352 65.3 (11.5) 358
Male, N (%) 227 (64.5%) 352 269 (75.1%) 358
Professional status, N (%)   352   357
  Working 122 (34.7%)   57 (16.0%)  
  Retired 186 (52.8%)   246 (68.9%)  
  Other 44 (12.5%)   54 (15.1%)  
BMI (kg/m 2 ), N (%)   349   358
  Underweight (<18) 10 (2.9%)   25 (7.0%)  
  Normal (18–25) 131 (37.5%)   138 (38.5%)  
  Overweight (25–30) 133 (38.1%)   121 (33.8%)  
  Obese (≥ 30) 75 (21.5%)   74 (20.7%)  
Current smoker, N (%) 195 (55.4%) 352 127 (35.6%) 357
Pulmonary hypertension, N (%) 12 (3.5%) 343 32 (9.2%) 348
≥1 cardiovascular comorbidity, N (%) 116 (33.0%) 352 138 (38.5%) 358
  Heart failure 44 (12.5%)   43 (12.0%)  
  Coronary heart disease 35 (9.9%)   62 (17.3%)  
  Peripheral artery disease 48 (13.6%)   45 (12.6%)  
  Other1 35 (9.9%)   55 (15.4%)  
COPD severity (investigator), N (%)   352   358
  Mild 49 (13.9%)   14 (3.9%)  
  Moderate 197 (56.0%)   151 (42.2%)  
  Severe 100 (28.4%)   152 (42.4%)  
  Very severe 6 (1.7%)   41 (11.5%)  
COPD severity (GOLD 2006), N (%)   137   323
  Grade 1 (mild) 31 (22.6%)   16 (5.0%)  
  Grade 2 (moderate) 62 (45.3%)   183 (56.6%)  
  Grade 3 (severe) 13 (9.5%)   38 (11.8%)  
  Grade 4 (very severe) 31 (22.6%)   86 (26.6%)  
COPD severity (GOLD 2011), N (%) 2   136   319
  Group A: Low risk, less symptoms 20 (14.7%)   71 (22.3%)  
  Group B: Low risk, more symptoms 15 (11.0%)   72 (22.6%)  
  Group C: High risk, less symptoms 45 (33.1%)   52 (16.3%)  
  Group D: High risk, more symptoms 56 (41.2%)   124 (38.9%)  
Median time in years since diagnosis (range) 5.0 (0–40) 347 4.0 (0–30) 352
FEV 1 , mean (SD) 3     
  % predicted 60.5 (22.8) 145 53.6 (16.7) 334
Arterial blood gas (mmHg), mean (SD)     
  PaO2 72.4 (12.8) 79 70.0 (11.7) 221
  PaCO2 42.1 (6.2) 66 41.2 (6.0) 218
Dyspnea (MRC grade), N (%)   349   353
  1 (strenuous exercise) 58 (16.6%)   24 (6.8%)  
  2 (walking upstairs or uphill) 146 (41.8%)   114 (32.3%)  
  3 (walking on the flat) 96 (27.5%)   103 (29.2%)  
  4 (walking slowly) 35 (10.0%)   77 (21.8%)  
  5 (daily activities) 14 (4.0%)   35 (9.9%)  
Chronic symptoms, N (%) 4     
  Daily expectorations 261 (74.6%) 350 232 (65.4%) 355
  Daily cough 307 (87.7%) 350 287 (81.1%) 354
  Daily expectorations + cough 245 (70.0%) 350 224 (63.3%) 354
Quality of life (CCQ) score, median 5   304   336
  Symptoms 3.3   2.8  
  Functional status 2.5   2.3  
  Mental status 2.0   2.0  
  Total 2.7   2.4  
History of repeated exacerbations, N (%) 6 222 (63.1%) 352 106 (29.6%) 358
  1. 1Excluding vascular (hypertension) and metabolic conditions (diabetes, hypercholesterolemia).
  2. 2A: GOLD 1–2 and < 1 exacerbation/year, MRC < 2; B: GOLD 1–2 and < 1 exacerbation/year, MRC ≥ 2; C: GOLD 3–4 and/or ≥ 2 exacerbations/year, MRC < 2; D: GOLD 3–4 and/or ≥ 2 exacerbations/year, MRC ≥ 2 [15].
  3. 3An additional 8 GP patients had FEV1 results which were aberrant and were excluded from the analysis; for one pulmonologist patient only FEV1 (L) was available (% FEV1 was missing).
  4. 4During the 3 months prior to initiation.
  5. 5During 7 days prior to initiation; score on a scale of 0 to 6 where 6 is the worst score.
  6. 6During the 12 months prior to initiation; exacerbation was defined as at least two of the following separated by at least 7 days over the last year: an emergency department visit, hospitalization, or a course of oral corticosteroids or antibiotics for respiratory problems.